These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 10500567)

  • 1. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 2. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Marcas LI; Manresa JM; Masramón J
    Transplant Proc; 1998 Aug; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract]   [Full Text] [Related]  

  • 3. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW
    Transplantation; 1995 Aug; 60(3):225-32. PubMed ID: 7645033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte subsets in renal transplant recipients treated with mycophenolate mofetil.
    François M; Büchler M; Halimi JM; Al-Najjar A; Valentin JF; Thibault G; Lebranchu Y
    Transplant Proc; 2000 Dec; 32(8):2781-2. PubMed ID: 11134803
    [No Abstract]   [Full Text] [Related]  

  • 5. Prospective study of mycophenolate mofetil for the prevention of acute rejection in living donor renal allograft recipients.
    Park K; Kim SI; Moon JI; Kim YS; Kim MS
    Transplant Proc; 1998 Nov; 30(7):3575. PubMed ID: 9838565
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Lerat L; Moreau A; Soulillou JP
    Nephrol Dial Transplant; 2000 Oct; 15(10):1673-6. PubMed ID: 11007839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients.
    Chueh SC; Huang CY; Lai MK
    Transplant Proc; 2000 Nov; 32(7):1901-2. PubMed ID: 11119992
    [No Abstract]   [Full Text] [Related]  

  • 8. Mycophenolate mofetil with lower cyclosporine dose in high-risk renal transplant recipients.
    Esmeraldo RM; Donadi MO; Oliveira ML; Ponte CN; Pinheiro PM
    Transplant Proc; 1999 Nov; 31(7):3007-8. PubMed ID: 10578367
    [No Abstract]   [Full Text] [Related]  

  • 9. A placebo controlled study of mycophenolate mofetil used in combination with cyclosporine and corticosteroids for the prevention of acute rejection in renal allograft recipients: 1-year results. The European Mycophenolate Mofetil Cooperative Study Group.
    Wiesel M; Carl S
    J Urol; 1998 Jan; 159(1):28-33. PubMed ID: 9400430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil versus azathioprine in simultaneous pancreas-kidney transplant recipients on cyclosporine.
    Fabrega AJ; Corwin CL; Hunsicker L
    Transplant Proc; 1998 Jun; 30(4):1562-3. PubMed ID: 9636634
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil as maintenance immunosuppression in pediatric renal transplantation.
    Ettenger R; Cohen A; Nast C; Moulton L; Marik J; Gales B
    Transplant Proc; 1997; 29(1-2):340-1. PubMed ID: 9123030
    [No Abstract]   [Full Text] [Related]  

  • 12. Mycophenolate mofetil in living donor renal allograft recipients.
    Park K; Moon JI; Kim SI; Kim YS
    Transplant Proc; 1999; 31(1-2):1133. PubMed ID: 10083506
    [No Abstract]   [Full Text] [Related]  

  • 13. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 14. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H; Moal V; Indreies M; Purgus R; Loundou A; Burtey S; Brunet P; Moussi-Frances J; Daniel L; Dussol B; Berland Y
    Transplantation; 2012 Feb; 93(4):437-43. PubMed ID: 22228415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycophenolate mofetil eliminates the rationale for antilymphocyte induction therapy in nonhaploidentical living-donor kidney transplants.
    Shaffer D; Madras PN; Conway P; Davis C; Simpson MA; Monaco AP
    Transplant Proc; 1997; 29(1-2):342-3. PubMed ID: 9123031
    [No Abstract]   [Full Text] [Related]  

  • 16. Mycophenolate mofetil for the prevention of acute rejection of primary cadaveric kidney transplants: status of the MYC 1866 study at 1 year. The U.S. Mycophenolate Mofetil Study Group.
    Transplant Proc; 1997; 29(1-2):348-9. PubMed ID: 9123033
    [No Abstract]   [Full Text] [Related]  

  • 17. Triple therapy with mycophenolate mofetil versus azathioprine.
    Muñiz ML; Amenabar J; Gómez-Ullate P; Urbizu J; Lampreabe I
    Transplant Proc; 1999; 31(1-2):1144-6. PubMed ID: 10083512
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy of mycophenolate mofetil treatment in the prevention of acute renal rejection is related to plasma level of mycophenolic acid.
    Kuriata-Kordek M; Boratyńska M; Klinger M; Woźniak M; Urbaniak J; Szyber P; Patrzalek D; Tupka D
    Transplant Proc; 2002 Nov; 34(7):2985-7. PubMed ID: 12431678
    [No Abstract]   [Full Text] [Related]  

  • 19. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 20. Reduction in the incidence of early rejection in cadaveric renal allograft recipients treated with ATGAM induction and sequential mycophenolate mofetil.
    Florence LS; Howard DR; Chapman PH; Lieberman J; Perkinson DT; Marks WH
    Transplant Proc; 1997; 29(1-2):313-4. PubMed ID: 9123016
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.